Close

SARS-CoV

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The SARS-CoV coronavirus, sometimes shortened to SARS-CoV, is the virus that causes severe acute respiratory syndrome (SARS-CoV). On April 16, 2003, following the outbreak of SARS-CoV in Asia and secondary cases elsewhere in the world, the World Health Organization (WHO) issued a press release stating that the coronavirus identified by a number of laboratories was the official cause of SARS-CoV.

Associated Disease
  • SARS
  • TCR Vector Products

  • TCR Viral Particles

Loading...
  • Target Species:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-L104 Human anti-SARS-CoV (GETALALLLL) T Cell Receptor, pMP71 SARS-CoV Human GETALALLLL HLA-B4001 retroviral vector   Add to Cart   Datasheet
TCR-L103Z Human anti-SARS-CoV (aa118-127) T cell receptor (Cysteine-modified), pCDTCR1 SARS-CoV Human GETALALLLL HLA-B4001 Lentiviral   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.